匹多莫德联合伐昔洛韦对复发性生殖器疱疹疗效及T细胞亚群的影响

Clinical effectiveness of pidotimod combined with valaciclovir in the treatment of recurrent genital herpes and its influence on T cell subsets

目的观察匹多莫德联合伐昔洛韦对复发性生殖器疱疹的疗效以及免疫功能的影响。方法将72例复发性生殖器疱疹患者随机分为2组,各36例,对照组单用伐昔洛韦片治疗,治疗组给予匹多莫德联合伐昔洛韦片治疗,2组患者均连续给药3个月。治疗前后分别抽取静脉血检测患者的免疫功能,并比较复发情况。结果与对照组相比,治疗组治疗后临床总有效率显著提高,平均复发次数明显降低,组间比较差异具有统计学意义(P<0.05)。治疗后,治疗组T淋巴细胞CD^(3+)、CD^(4+)、CD^(4+)/CD^(8+)比值升高,CD^(8+)降低,与对照组比较差异有统计学意义(P<0.05)。结论匹多莫德联合伐昔洛韦对复发性生殖器疱疹患者的免疫功能具有调节作用,疗效显著,并能减少复发次数,值得临床推广应用。

Objective To observe the clinical effectiveness of pidotimod combined with valaciclovir in the treatment of recurrent genital herpes(GH)and its influence on immune function.Methods A total of 72 recurrent GH patients were randomly divided into two groups(n=36):a control group and a treatment group.The control group was administered with valaciclovir tablets alone,while the treatment group was given pidotimod combined with valaciclovir tablets.Both groups were administered for consecutive three months.The venous blood samples were collected to evaluate their immune function before and after treatment,and the recurrence rate of the two groups was compared.Results Compared with the control group,the treatment group presented remarkable increases in the total clinical effective rate,with decreases in the recurrent rate(P<0.05).After treatment,the percentage of CD^(3+)and CD^(4+),and CD^(4+)/CD^(8+)ratio increased but the percentage of CD^(8+)decreased(P<0.05).Conclusions Pidotimod combined with valaciclovir can exert immune modulatory effects on recurrent GH patients,with good clinical effectiveness and reduced recurrence rate.